A Phase 2a, 4-Week, Single Arm, Open-label, Multi-center Study to Assess Safety, Tolerability, and Preliminary Efficacy of NOE-115 in Women With Vasomotor Symptoms Due to Menopause
Latest Information Update: 01 Dec 2025
At a glance
- Drugs Cendifensine (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Adverse reactions
- Sponsors Noema Pharma
Most Recent Events
- 06 Nov 2025 Results published in the Media Release
- 12 Sep 2025 Status changed from active, no longer recruiting to completed.
- 06 May 2025 Planned End Date changed from 30 Apr 2025 to 30 Sep 2025.